GlassScriptPhysician profile
Mark A Seiden
NPI 1588770390
$19,674.23
in general payments reported to CMS, 2019-2025
37 companies · $638 in 2025
The $638 reported for 2025 was more than what 78% of Foot Surgery providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $139 · 2021: $194 · 2022: $1,796 · 2023: $558 · 2024: $600 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,795.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acell, INC. | $15,479.29 | 2019 | |
| Titan Surgical Group, LLC | $1,254.62 | 2022-2025 | |
| Smith+Nephew, INC. | $587.43 | 2019-2025 | Collagenase Santyl, Grafix |
| Paratek Pharmaceuticals, INC. | $292.10 | 2023-2025 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $277.34 | 2022-2023 | Seglentis |
| Globus Medical, INC. | $232.59 | 2025 | Senza |
| Acera Surgical, INC. | $218.54 | 2020-2025 | Restrata Wound Matrix |
| Stryker Corporation | $133.08 | 2024-2025 | Ortholoc 3di, Dart-Fire, Prostep Mica |
| Organogenesis INC. | $125.53 | 2021-2025 | Puraply, Cygnus Dual |
| Kerecis Limited | $103.63 | 2022-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Graftguide |
| Mimedx Group, INC. | $88.82 | 2024-2025 | |
| Rikco International, LLC | $86.00 | 2019 | |
| Alfasigma USA, INC. | $67.37 | 2020 | |
| Depuy Synthes Sales INC. | $65.86 | 2024 | Motoband, Motoband Cp, Minibunion |
| Integra Lifesciences Corporation | $64.86 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $58.33 | 2023-2025 | Eterna |
| Polynovo North America LLC | $47.08 | 2024 | Novosorb Btm |
| Bioventus LLC | $43.54 | 2019-2021 | |
| Djo, LLC | $40.29 | 2024 | Cmf |
| Horizon Therapeutics Plc | $39.86 | 2022-2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $37.90 | 2019 | |
| Baudax Bio INC. | $34.96 | 2020-2021 | |
| Treace Medical Concepts, INC. | $29.14 | 2024-2025 | |
| Biotissue Holdings INC. | $28.81 | 2023 | |
| Boston Scientific Corporation | $27.40 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Next Science LLC | $25.34 | 2024 | Xperience, Blastx, Surgx |
| Averitas Pharma INC. | $22.53 | 2023 | Qutenza |
| Solventum Corporation | $22.44 | 2024 | Activ.A.C. |
| Nevro Corp. | $21.52 | 2024 | Senza |
| Biocomposites INC | $17.43 | 2025 | Stimulan |
| Zimmer Biomet Holdings, INC. | $16.00 | 2019 | |
| Aroa Biosurgery Incorporated | $15.82 | 2019-2020 | |
| Amgen INC. | $15.36 | 2025 | Krystexxa |
| Sandoz INC. | $14.80 | 2019 | |
| Abbvie INC. | $14.78 | 2022 | |
| Medtronic, INC. | $13.50 | 2023 | Intellis Adaptivestim |
| Arteriocyte Medical Systems, INC. | $10.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Seiden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.